Core Viewpoint - Windtree Therapeutics, Inc. has signed an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC, which includes a revenue-sharing arrangement and contingent payments based on future financing [1][2][3] Group 1: Agreement Details - Windtree will receive 20% of any milestone payments, royalty payments, or similar economic interests from Seismic, including all global commercial net revenues related to acute heart failure (AHF) if approved [1][2] - Windtree is entitled to a payment of $700,000 from Seismic contingent on a financing round that results in gross cash proceeds of at least $10,000,000 [1][2] - As part of the agreement, Windtree will transfer certain cardiovascular development payables to Seismic [1][2] Group 2: Market Potential - In 2022, there were 2.1 million AHF hospital admissions in the US and 2.7 million in the EU, indicating a significant market for AHF treatments [2] - Windtree believes the global drug market value for AHF is in the billions of dollars, highlighting the potential financial upside of the agreement [2] Group 3: Company Statements - The CEO of Windtree expressed satisfaction with the agreement, emphasizing the non-dilutive cash flow and the elimination of funding obligations for development while retaining rights to future payments [3] - The company aims to focus on becoming a revenue-generating entity with future profitability [4]